Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Abstract Introduction Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. Methods This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalido...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70072 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849706405381013504 |
|---|---|
| author | Barry Paul Jiri Minarik Francesca Cottini Cristina Gasparetto Jack Khouri Mitul Gandhi Jens Hillengass Moshe Levy Michaela Liedtke Sudhir Manda Irwindeep Sandhu Douglas Sborov Ivan Spicka Saad Usmani Mei Dong Lin Gu Carmen Leung Parul Doshi Christine Chen Ludek Pour |
| author_facet | Barry Paul Jiri Minarik Francesca Cottini Cristina Gasparetto Jack Khouri Mitul Gandhi Jens Hillengass Moshe Levy Michaela Liedtke Sudhir Manda Irwindeep Sandhu Douglas Sborov Ivan Spicka Saad Usmani Mei Dong Lin Gu Carmen Leung Parul Doshi Christine Chen Ludek Pour |
| author_sort | Barry Paul |
| collection | DOAJ |
| description | Abstract Introduction Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. Methods This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR). Results ORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose‐limiting toxicities: febrile neutropenia (Magro+Dara) and infusion‐related reaction (Magro+Pd). Grade ≥ 3 Magro‐related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE‐related; neither was Magro related. Conclusion As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited. Trial Registration This trial was registered at www.clinicaltrials.gov as #NCT04892446 |
| format | Article |
| id | doaj-art-bcd228912f614c23bbfa784f7fc64efa |
| institution | DOAJ |
| issn | 2688-6146 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj-art-bcd228912f614c23bbfa784f7fc64efa2025-08-20T03:16:12ZengWileyeJHaem2688-61462025-06-0163n/an/a10.1002/jha2.70072Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaBarry Paul0Jiri Minarik1Francesca Cottini2Cristina Gasparetto3Jack Khouri4Mitul Gandhi5Jens Hillengass6Moshe Levy7Michaela Liedtke8Sudhir Manda9Irwindeep Sandhu10Douglas Sborov11Ivan Spicka12Saad Usmani13Mei Dong14Lin Gu15Carmen Leung16Parul Doshi17Christine Chen18Ludek Pour19Atrium Health Levine Cancer Institute Wake Forest University School of Medicine Charlotte North Carolina USAFakultni Nemocnice Olomouc Olomouc Czech RepublicThe Ohio State University Columbus Ohio USADuke Cancer Institute Durham North Carolina USACleveland Clinic Cleveland Ohio USAUS Oncology Site, Virginia Cancer Specialists Fairfax Virginia USARoswell Park Cancer Institute Buffalo New York USABaylor University Medical Center Dallas Texas USAStanford Cancer Center Palo Alto California USAArizona Oncology Associates Tucson Arizona USACross Cancer Institute Edmonton Alberta CanadaHuntsman Cancer Institute at the University of Utah Salt Lake City Utah USACharles University Hospital Kralovske Vinohrady Prague Czech RepublicMemorial Sloan‐Kettering Cancer Center New York New York USAGilead Sciences, Inc Foster City California USAGilead Sciences, Inc Foster City California USAGilead Sciences, Inc Foster City California USAGilead Sciences, Inc Foster City California USAPrincess Margaret Cancer Centre Toronto Ontario CanadaUniversity Hospital Brno Brno Czech RepublicAbstract Introduction Patients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy. Methods This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR). Results ORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose‐limiting toxicities: febrile neutropenia (Magro+Dara) and infusion‐related reaction (Magro+Pd). Grade ≥ 3 Magro‐related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE‐related; neither was Magro related. Conclusion As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited. Trial Registration This trial was registered at www.clinicaltrials.gov as #NCT04892446https://doi.org/10.1002/jha2.70072carfilzomibdaratumumabdexamethasonemagrolimabpomalidomiderelapsed/refractory multiple myeloma |
| spellingShingle | Barry Paul Jiri Minarik Francesca Cottini Cristina Gasparetto Jack Khouri Mitul Gandhi Jens Hillengass Moshe Levy Michaela Liedtke Sudhir Manda Irwindeep Sandhu Douglas Sborov Ivan Spicka Saad Usmani Mei Dong Lin Gu Carmen Leung Parul Doshi Christine Chen Ludek Pour Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma eJHaem carfilzomib daratumumab dexamethasone magrolimab pomalidomide relapsed/refractory multiple myeloma |
| title | Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma |
| title_full | Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma |
| title_fullStr | Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma |
| title_full_unstemmed | Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma |
| title_short | Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma |
| title_sort | final results of a phase 2 multi arm study of magrolimab combinations in patients with relapsed refractory multiple myeloma |
| topic | carfilzomib daratumumab dexamethasone magrolimab pomalidomide relapsed/refractory multiple myeloma |
| url | https://doi.org/10.1002/jha2.70072 |
| work_keys_str_mv | AT barrypaul finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT jiriminarik finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT francescacottini finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT cristinagasparetto finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT jackkhouri finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT mitulgandhi finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT jenshillengass finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT moshelevy finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT michaelaliedtke finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT sudhirmanda finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT irwindeepsandhu finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT douglassborov finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT ivanspicka finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT saadusmani finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT meidong finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT lingu finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT carmenleung finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT paruldoshi finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT christinechen finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma AT ludekpour finalresultsofaphase2multiarmstudyofmagrolimabcombinationsinpatientswithrelapsedrefractorymultiplemyeloma |